Discovery of selective JAK1/2 inhibitor H018, a phase II agent with demonstrated preclinical anti-rheumatoid arthritis activity.

KFP-H018 - Carephar Pharma

Jyseleca (filgotinib) - Gilead

http://www.ncbi.nlm.nih.gov/pubmed/41795417

Haifeng Zhu; Hongfan Wang; Jing Yang; Mei Su; Peng Wang; Shuai Li

Mar 8, 2026